Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein

Cancer Biotherapy and Radiopharmaceuticals

Volumn 16, Issue 1, 2001, Pages 1-7

  Ballinger, J R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE ANTIBIOTIC AGENT; BIRICODAR; BUTHIONINE SULFOXIMINE; CARBON 11; COLCHICINE; CYCLOSPORIN A; DAUNORUBICIN; DEXVERAPAMIL; ELACRIDAR; EPIPODOPHYLLOTOXIN DERIVATIVE; GLUTATHIONE; GLYCOPROTEIN P; GLYCOPROTEIN P MODULATOR; LEUKOTRIENE E4; LUNG RESISTANCE PROTEIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN; PROTEINASE INHIBITOR; QUINIDINE; RHODAMINE 123; TAXANE DERIVATIVE; TETROFOSMIN; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINCA ALKALOID; ZOSUQUIDAR;

BREAST CARCINOMA; CANCER CELL; CANCER RESISTANCE; DRUG CLEARANCE; EDITORIAL; HUMAN; ISOTOPE LABELING; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0035077780     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497801750095907     Document Type: Editorial

References (60)

1. Mechanism of drug resistance
2. Multidrug resistance transporters and modulation
3. Modulation of multidrug resistance: At the threshold
4. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
5. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16
6. Evaluation of multidrug resistant phenotype by flow cytometry with monoclonal antibodies and functional tests
7. Pharmacology of drugs that alter multidrug resistance in cancer
8. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen
9. Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins
10. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative
11. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
12. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel
13. Involvement of the glutathione S-conjugate compounds and the MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake in glioma cell lines
14. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein
15. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP
16. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex
17. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients
18. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer
19. Clinical imaging of multidrug resistance in cancer
20. Scintigraphic detection of multidrug resistance in cancer
21. Visualization of multidrug resistance in vivo
22. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
23. Technetium-99m-tetrofosmin would be a substrate for multidrug resistance-associated protein (MRP): Comparison between a leukemia cell line with high MRP gene expression and its parental cell line
24. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ ABCP on the transport of 99mTc-tetrofosmin
25. Comparison of the accumulation and efflux kinetics of technetium-99m-sestamibi and technetium-99m-tetrofosmin in an MRP-expressing tumor cell line
26. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET
27. Evaluation of 11C-colchicine for PET imaging of multiple drug resistance
28. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography
29. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier
30. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer
31. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography
32. Comparative study of Tc-99m MIBI and T1-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer
33. Evaluation of radiotherapeutic response in non-small cell lung cancer patients by technetium-99m MIBI and thallium-201 chloride SPET
34. Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer
35. Pulmonary Tc-99m tetrofosmin imaging: Clinical experience with detecting malignant lesions and monitoring response to therapy
36. Evaluation of chemotherapy response in patients with small cell lung cancer using technetium-99m-tetrofosmim
37. Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma: Technetium-99m-tetrofosmin and thallium-201 dual single photon emission computed tomography study
38. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography
39. Preoperative evaluation of the chemosensitivity of breast cancer by means of double phase 99mTc-MIBI scintimammography
40. The role of 99Tcm-sestamibi scintigraphy in the staging and prediction of the therapeutic response of stage IV neuroblastoma: Comparison with 131I-MIBG and 99Tcm-MDP scintigraphy
41. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients
42. Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results
43. Technetium-99m tetrofosmin mammoscintigraphy findings related to the expression of P-glycoprotein mediated multidrug resistance
44. Tc-99m MIBI SPECT is useful for noninvasively predicting the presence of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma
45. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein
46. Tc-99m MIBI to evaluate children with Ewing's sarcoma
47. Why haven't we cured multidrug resistant tumors?
48. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug insurance inhibitor GG918
49. Efflux of rhodamine from CD56(+) cells as a surrogate marker for reversal of P-glycoprotein-mediated drag efflux by PSC 833
50. Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo
51. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi
52. 99mTc-sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours
53. The effect of P-glycoprotein function inhibition with cyclosporine A on the biodistribution of Tc-99m sestamibi
54. Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas
55. Tc-99m-tetrofosmin in breast carcinoma and axillary lymph node metastases: A comparative study with Tc-99m MIBI
56. A head-to-head comparison between technetium-99m-tetrofosmin and technetium-99m-MIBI scintigraphy to evaluate suspicious breast lesions
57. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: Human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging
58. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: Human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent
59. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
60. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors